| Identification | Back Directory | [Name]
Acetic acid, 2-[4-[[(2E)-3-(4-fluorophenyl)-3-[4-[3-(4-morpholinyl)-1-propyn-1-yl]phenyl]-2-propen-1-yl]oxy]-2-methylphenoxy]-, sodium salt (1:1) | [CAS]
1604815-32-8 | [Synonyms]
HPP593
HPP593|||REN001|||REN001 | [Molecular Formula]
C31H30FNO5.Na | [MOL File]
1604815-32-8.mol | [Molecular Weight]
538.56 |
| Hazard Information | Back Directory | [Uses]
Mavodelpar (REN001) is a selective PPARδ agonist. Mavodelpar suppresses glomerular injury and renal fibrosis. Mavodelpar can be used for the research of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD)[1]. Mavodelpar is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. | [in vivo]
Mavodelpar (10 mg/kg; i.p., once daily, from 6 to 17 weeks of age) effectively suppresses glomerular injury and renal fibrosis, and decreases levels of fibrosis-related proteins[1]. | Animal Model: | Male and female B6129SF1-Col4a3-/- mice[1] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection; 10 mg/kg, once daily, from 6 to 17 weeks of age | | Result: | Suppressed proteinuria and blood urea nitrogen (BUN) levels. Reduced glomerular injury, renal fibrosis, phosho-Stat3 and connective tissue growth factor (CTGF) levels. Decreased the expression level of the activated fibroblast marker alpha-SMA and Collagen I and IV.
|
| [References]
[1] Omachi K, et al. PPARδ agonism ameliorates renal fibrosis in an Alport syndrome mouse model. Kidney360. 2022 Nov 29. DOI:10.34067/KID.0006662022 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|